RBC keeps Medicis at outperform

Medicis Pharmaceutical Corp. was kept at outperform, above average risk, and a $34 price target by RBC Capital Markets analyst Ken Trbovich on news of IMS Health data for the week ending Aug. 25 showing 6,645 prescriptions for Solodyn. Total prescriptions are up about 5.4% compared to the prior week. Oral acne prescriptions continue on pace above the analyst's estimates. While the old Dynacin brand prescriptions declined slightly to 2,417 from 2,424, Medicis' acne franchise is up 75% from the comparable week last year. Combined prescriptions of 9,063 are on track to exceed 32,000 prescriptions in the month of August. RBC believes peak potential for Solodyn is between $175 million and $250 million in annual gross sales. Shares of the Scottsdale, Ariz.-based specialty pharmaceutical company were up 31 cents, or 1.05%, at $29.94, on volume of 1,109,600 shares versus the three-month running average of 1,167,510 shares. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.